US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
CNS Pharmaceuticals, Inc. - Common Stock
(NQ:
CNSP
)
5.325
+0.084 (+1.61%)
Delayed Quote
Updated: 3:58 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CNS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
24
25
Next >
Researchers Develop Novel Way to Detect Pediatric Brain-Cancer Mutations
August 17, 2023
Via
Investor Brand Network
How Healthcare eCommerce Impacts Traditional Providers of Healthcare
August 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
August 14, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
August 14, 2023
Via
ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
August 14, 2023
Via
ACCESSWIRE
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
August 03, 2023
Via
ACCESSWIRE
Researchers Trace Glioma Brain Tumor Origins to Epigenome
July 31, 2023
Via
Investor Brand Network
CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
Via
ACCESSWIRE
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
August 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
August 07, 2023
Via
Investor Brand Network
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
↗
August 07, 2023
Watch the full show here! John Climaco, Chairman & CEO of CNS Pharmaceuticals (NASDAQ: CNSP) presented at Benzinga’s webinar: Pharma Companies Vs. A Tough Macro Backdrop.
Via
Benzinga
Researchers Unlock Previously Unknown Weakness of Brain Cancer
August 04, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 14, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
August 03, 2023
Via
Investor Brand Network
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
August 03, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference
July 27, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
July 27, 2023
Via
ACCESSWIRE
Clinical Trial Testing Modified Viruses as Brain Cancer Treatment Begins
July 25, 2023
Via
Investor Brand Network
National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
July 21, 2023
Via
Investor Brand Network
Doctors Use Melanoma Drugs to Shrink Brain Tumors by 90% in Small Study
July 19, 2023
Via
Investor Brand Network
Harvard Scientists Create AI Tool to Provide Real-Time Genetic Analysis of Brain Cancer During Surgery
July 14, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Biochemist Working to Make Chemo Sans Side Effects
July 07, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series
July 05, 2023
Via
Investor Brand Network
Immunotherapy Implants Could Turn Tumor Cells on Each Other
June 30, 2023
Via
Investor Brand Network
Virus Therapy Plus Radiation Could Improve Brain Tumor Treatment, Study Finds
June 26, 2023
Via
Investor Brand Network
Experimental Vaccine Brings Hope of Slowing Glioblastoma Tumor Regrowth
June 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference
June 15, 2023
Via
Investor Brand Network
Researchers Explain How Brain Cancers Hijack Neural Circuits
June 13, 2023
Via
Investor Brand Network
Scientists Create Open-Source Platform to Analyze Brain Tumors in Kids
June 07, 2023
Via
Investor Brand Network
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
June 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
24
25
Next >
